BeCool
Pharmaceutics
Erasing death and disability
from brain and spinal cord injury
Overview

Over 500,000 Americans suffered cardiac arrest last year. Only 10% survived and were able to go home or to assisted living. Most died and those who survived required long term care.

Overview

Over 500,000 Americans suffered cardiac arrest last year. Only 10% survived and were able to go home or to assisted living. Most died and those who survived required long term care.

Team

Kelly L. Drew, phd

Chief Executive Officer

Publications

Prof. Drew serves in the Department of Chemistry and Biochemistry at the University of Alaska Fairbanks with over 70 peer-reviewed publications and 30 years experience in biomedical research focused on hibernation and brain injury.

Bernard W. Laughlin, DO

Chief Scientific Officer

Publications

Clinician/Scientist leading preclinical studies.

Numerous student and graduate researchers are also participating on this development.

Invest

Why Invest?

Bottom up market analysis estimates an annual serviceable obtainable market of $3B to generate $150M annually through earned royalties.

Target Market

Total available market of 1,445,000 patients includes tertiary care for out of hospital cardiac arrest (OHCA) as a primary indication and stroke, spinal cord injury and hypoxic ischemic encephalopathy as secondary indications.

Business Model

BeCool Pharmaceutics is a small molecule drug development company, focused on creating therapeutics to modulate metabolism and body temperature by mimicking mechanisms used in hibernation.

BCP 019 follows a traditional drug development model.

Achievements

  • Preclinical validation
  • At IND enabling stage
  • Continuing preclinical large and small animal efficacy studies
  • NIH SBIR Phase I awarded
  • M.J. Murdock Charitable Trust, Commercialization grant awarded
Contact

Kelly Drew
907.388.5311
kdrew@becoolpharma.com